LF

LEIGH FAIRLEY

ARNOLD & PORTER KAYE SCHOLER LLP · Washington, DC · registered since 2024
Registered · LDAActive

At a glance

Registered since
2024
Senate LDA system
Clients
2
last 3 years
Filings
6
5 agencies contacted
Activity
filings by quarter
Works on

Background

Government experience
Intern
Sen. Portman
2017
Disclosed on LD-2 filings
Career
Washington, DC
2024 - present

Specific issues

Issues related to implementation of the Inflation Reduction Act (IRA, P.L. 117-169).
Medicare/Medicaid · 2024 Q3
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Health Issues · 2024 Q3
Issues related to implementation of the Inflation Reduction Act (IRA, P. L. 117-169).
Medicare/Medicaid · 2024 Q3
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Health Issues · 2024 Q2
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Health Issues · 2024 Q1

Clients

$██,███ / qtrUnlock
$██,███ / qtrUnlock

Filing history

2024 Q3
PHARMAESSENTIA USA CORPORATION
Q3lda.gov →
2024 Q3
GENETIX BIOTHERAPEUTICS, INC.
Q3lda.gov →
2024 Q3
PHARMAESSENTIA USA CORPORATION
RAlda.gov →
2024 Q3
PHARMAESSENTIA USA CORPORATION
RRlda.gov →
2024 Q2
GENETIX BIOTHERAPEUTICS, INC.
Q2lda.gov →
2024 Q1
GENETIX BIOTHERAPEUTICS, INC.
Q1lda.gov →
Showing recent filings · full history on lda.gov